Investigating whether such drugs could also benefit T1D patients with obesity could be promising
For example, curcumin has been evaluated in Phase II clinical studies in pancreatic cancer and colorectal cancer patients, where oral doses up to 8 g/day demonstrated acceptable safety but limited systemic exposure, highlighting pharmacokinetic challenges
my heart urged and so I did
Lancet 397(10278):971984 Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D et al (2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Activation of the nuclear factor erythroid 2related factor 2 (Nrf2) pathway directly raises GSH levels, upregulates the transcription of genes involved in antioxidant defense, provides mitochondrial protection, facilitates the proliferation of detoxification enzymes and modulates neuroinflammation (Guerrero-Beltrn et al., 2012
